Quality Control of Mitochondria in Parkinson’s disease (PD) Using ATP and Bradford Assays
Al-Baraa Akram El-Sayed*
Corresponding Author: Al-Baraa Akram El-Sayed, Department of Pharmaceutical Biotechnology, Portland laboratory, De Montfort University, Leicester, UK.
Revised: August 25, 2022; Available Online: August 25, 2022
Citation: El-Sayed Al-BA. (2022) Quality Control of Mitochondria in Parkinson’s disease (PD) Using ATP and Bradford Assays. J Neurosurg Imaging Techniques, 7(S1): 01.
Copyrights: ©2022 El-Sayed Al-BA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 100

    Views & Citations
Parkinson’s disease is a heterogeneous, multifactorial and often complex disease characterized by motor impairment due to the presence of Lewy bodies and prominent degeneration of dopaminergic neurons in the substantia nigra. Although the specific pathogenesis involving PD remains under investigation, mitochondrial dysfunction has been widely accepted as one of the major pathogenic pathways underlying the development of PD. Based on the hypothesis that depiction of HtrA2 (serine protease gene, mitochondrial precursor) might contribute to an increase in mitochondrial stress and transcriptional up regulation of the nuclear stress response CHOP gene. The present study aimed to analyze through laboratory based research the role of HtrA2 and CHOP in the transmission of stress signaling and the consequent activation of mitochondrial quality control in Parkinson's disease using ATP and Bradford assays.

Keywords: Parkinson's disease, Lewy bodies, Mitochondrial dysfunction, Bradford assays